<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528060</url>
  </required_header>
  <id_info>
    <org_study_id>2007-003203-12</org_study_id>
    <nct_id>NCT00528060</nct_id>
  </id_info>
  <brief_title>Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada</brief_title>
  <acronym>ANRS134COPHAR3</acronym>
  <official_title>Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the trial assessed the pharmacokinetics and long term plasma exposure of the following
      antiretrovirals: atazanavir when combined to ritonavir and the tenofovir/emtricitabine
      fixed-dose combination. All drugs will be delivered in MEMS electronic device to monitor
      dosing history.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a phase II, open label, non-randomized, prospective multicenter trial to assess
      the pharmacokinetics and long term plasma exposure of the following antiretrovirals:
      atazanavir when combined to ritonavir and the tenofovir/emtricitabine fixed-dose combination.
      All drugs will be delivered in MEMS electronic device to monitor dosing history.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic parameters of atazanavir (ATV) when combined with ritonavir (RTV) and tenofovir/emtricitabine</measure>
    <time_frame>week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics of emtricitabine and tenofovir; intraindividual variability in ARVs concentrations; adherence measured with MEMS records and validated ANRS observance autoquestionnaire; relationships between virological response or side event occurrence</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>2pills/day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>1 pill/day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir/emtricitabine</intervention_name>
    <description>1 pill/day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naïve of treatment HIV -1 infected patients

          -  CD4 above 100/mm3

        Exclusion Criteria:

          -  pregnancy

          -  renal failure

          -  hepatitic disease

          -  ongoing opportunistic disease

          -  Hb under 8g/dl; platelets under 50 000/mm3; neutrophils under 750/mm3; Prothrombin
             index under 80%, Ca or Ph &gt; 2.5 N

          -  drugs interacting with investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cécile Goujard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Kremlin-Bicetre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>France Mentre, PHD</last_name>
    <role>Study Director</role>
    <affiliation>AP-HP Bichat, Inserm U738</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital du Kremlin Bicêtre Service de médecine interne</name>
      <address>
        <city>Kremlin Bicëtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat CIC</name>
      <address>
        <city>Paris cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2007</study_first_submitted>
  <study_first_submitted_qc>September 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2007</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infections</keyword>
  <keyword>atazanavir</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

